




**RESILIENT BIOTICS**

**CHRIS BELNAP, PHD  
CEO AND CO-FOUNDER  
[chris.belnap@resilientbiotics.com](mailto:chris.belnap@resilientbiotics.com)**



# PROBLEM: ANTIBIOTIC RESISTANCE


A 3D rendering of several clusters of spherical, teal-colored microorganisms, likely bacteria, against a dark red background. The clusters vary in size and are arranged in a way that suggests a growing population.

**Antibiotic Resistant  
Microorganisms**




# MICROBIOME THERAPEUTICS TO STOP DISEASE

- Microbiome-derived
- Live microbial formulations
- Therapeutic properties
- Antibiotic alternative





# NEXT-GEN DISCOVERY AND VALIDATION PLATFORM



## Product #1:

Bovine respiratory disease

## Product #2:

Collaboration – bovine target

## Product #3:

2<sup>nd</sup> respiratory target (2020)

## Product #4:

2<sup>nd</sup> collaboration target (2020)



# RESPIRATORY APPLICATION: BOVINE RESPIRATORY DISEASE

**Bovine Respiratory Disease (BRD) causes massive economic losses to the cattle industry**

- Controlled with antibiotic metaphylaxis and treatment
- Lack of effective preventative treatments




“If you can offer a non-antibiotic treatment for BRD, people would line up to buy it.”  
- Feedlot veterinarian

“BRD is by far the biggest concern.”  
- Feedlot manager

“A preventative treatment is more desirable.”  
- Feedlot manager

# DESIGNING A BETTER THERAPEUTIC



## Lead Product:

- Live strain mix designed for BRD protection
- Intranasal delivery
- Proprietary and IP protected consortia
- Multiple modes of action
- Sold as a veterinary therapeutic



# 60% DISEASE REDUCTION

## Proof of Concept *in vivo* BRD challenge


- Challenge with virus + *M. haemolytica*

## Lead formulation

- Proprietary 3 strain mix

## Results

- 60% reduction of lung infection
- 75% less *M. haemolytica* colonization





# DISRUPTIVE PRODUCT

## Ruminant Health Market

- \$3.3 Billion (USA & Canada)


## Cattle Respiratory Treatments

- \$600-\$700 Million (USA & Canada)\*

## Microbiome Therapeutic

- Disruptive product that could take vaccine and anti-infective market share

BRD Treatment Peak Revenue  
USA & Canada, 20% penetration



\* internal calculations





# LEADERSHIP TEAM



**Christopher Belnap**  
Co-Founder and CEO  
Board member



Leader in microbiome product development



**Greg Werner**  
Co-Founder and CTO  
Board Observer



Expert in bioinformatics, AI, and data science



**Rachelle Galvin**  
COO



R&D Strategy and animal health expert

## Agtech Accelerator



**John Dombrosky**  
Business Strategy



**Tracy Jackson**  
Finance



**Megan Lyman**  
IP Strategy

## Board Members



**Corey Huck**  
Global Head  
Biologicals, Syngenta



**Eric Easom**  
CEO, AN2  
Therapeutics



# PRODUCT PIPELINE

